Clinical evaluation of a fluorescence-based rapid beta-lactam antibiotic test for point-of-care diagnostics in human blood

Clinical evaluation of a fluorescence-based rapid beta-lactam antibiotic test for point-of-care diagnostics in human blood - SNiPoCC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040213

Enrollment

180

Registered

2026-05-07

Start date

2023-10-30

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A49

Interventions

Group 1: Patient group – a portion of the routine blood sample is centrifuged, and the rapid test developed for determining antibiotic levels is performed using the serum. Antibiotic levels are determ

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Valid informed consent form (prospective, retrospective, or provided by a legal representative), antibiotic therapy with piperacillin in the intensive care unit or intermediate care unit of the Department of General Surgery at UMG

Exclusion criteria

Exclusion criteria: Patients without a valid informed consent form

Design outcomes

Primary

Measure	Time frame
Blood levels of piperacillin are measured both through routine clinical testing and using the newly developed rapid test. Blood samples are collected once a day for this purpose. Changes in blood levels are monitored over several days.	—

Countries

Germany

Contacts

Public ContactThorsten Perl

Universitätsmedizin Göttingen Klinik für Allgemein-, Viszeral- und Kinderchirurgie

thorsten.perl@med.uni-goettingen.de+49 551 3991021

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026